Physician profile
Sinia Rios
NPI 1477510063
$5,787.50
in general payments reported to CMS, 2019-2025
14 companies · $1,481 in 2025
The $1,481 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $745 · 2020: $261 · 2021: $312 · 2022: $744 · 2023: $1,115 · 2024: $1,130 · 2025: $1,481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,725.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,576.29 | 2019-2025 | Otezla, Evenity, Enbrel |
| Abbvie INC. | $1,080.25 | 2019-2025 | Rinvoq |
| Astrazeneca Pharmaceuticals LP | $399.64 | 2023-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $370.21 | 2019-2025 | Orencia, Sotyktu |
| Glaxosmithkline, LLC. | $366.01 | 2024-2025 | Benlysta |
| Janssen Pharmaceuticals, INC | $217.21 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $179.33 | 2019-2023 | |
| Janssen Biotech, INC. | $125.29 | 2025 | Simponi Aria, Tremfya |
| Genzyme Corporation | $114.95 | 2019-2023 | |
| Ucb, INC. | $107.95 | 2025 | Bimzelx |
| Eli Lilly Export S.A. Puerto Rico Branch | $84.85 | 2023-2024 | Taltz |
| Pbg Puerto Rico LLC | $75.25 | 2019-2022 | |
| Organon LLC | $46.52 | 2023-2025 | |
| Horizon Therapeutics Plc | $43.75 | 2023 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sinia Rios listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.